<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound	</title>
	<atom:link href="https://www.novumpr.nl/2016/06/06/new-data-on-olmutinib-bi-1482694-presented-at-asco-2016-underscores-clinical-potential-of-boehringer-ingelheims-next-generation-lung-cancer-compound/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2016/06/06/new-data-on-olmutinib-bi-1482694-presented-at-asco-2016-underscores-clinical-potential-of-boehringer-ingelheims-next-generation-lung-cancer-compound/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-data-on-olmutinib-bi-1482694-presented-at-asco-2016-underscores-clinical-potential-of-boehringer-ingelheims-next-generation-lung-cancer-compound</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Mon, 06 Jun 2016 10:20:58 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
